Effects of online hemodiafiltration on anemia and nutritional status in chronic hemodialysis patients
Background : : Online hemodiafiltration (OL-HDF) offers considerable advantages in clearance of molecules of various sizes. However, evidence of clinical effects of OL-HDF is scarce in Korea. In this study, we investigated changes in laboratory values over more than 12 months after switching to OL-HDF. Methods : : Adult patients with end-stage renal disease undergoing hemodialysis (HD) were prospectively enrolled in a K-cohort (CRIS no. KCT0003281) from 6 tertiary hospitals in South Korea. We recruited 435 patients, 339 of whom were on HD at enrollment. One hundred eighty-two patients were followed for more than 24 months. Among them, 44 were switched to OL-HDF for more than 12 months without conversion to HD. We used a paired t test to compare baseline and 24-month follow-up results. Results : : The mean age of the subjects was 61.2 ± 12.2 years, and 62.6% were male. The baseline hemoglobin level was not significantly different between HD and OL-HDF group (10.61 ± 1.15 vs. 10.46 ± 1.03 g/dL, P = 0.437). However, the baseline serum protein and albumin levels were significantly lower in the OL-HDF group (6.82 ± 0.49 vs. 6.59 ± 0.48 g/dL, P = 0.006; 3.93 ± 0.28 vs. 3.73 ± 0.29 g/dL, P < 0.001). In patients switched to OL-HDF, levels of hemoglobin and serum albumin significantly increased (10.46 ± 1.03 vs. 11.08 ± 0.82 g/dL, P = 0.001; 3.73 ± 0.29 vs. 3.87 ± 0.30 g/dL, P = 0.001). The normalized protein catabolic rate decreased after 24 months, but the change was not significant (1.07 ± 0.25 vs. 1.03 ± 0.21 g/kg/day, P = 0.433). Although the dose of erythropoiesis-stimulating agent was lower in patients who converted to HDF, it was not significantly different (-115.7 ± 189.7 vs. -170.5 ± 257.1 P = 0.206). Conclusion : : OL-HDF treatment over more than 12 months was associated with no harmful effects on anemia and nutritional status..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Kidney Research and Clinical Practice - 39(2020), 1, Seite 103-111 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Yu Ho Lee [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anemia |
|---|
| doi: |
10.23876/j.krcp.19.082 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ046957529 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ046957529 | ||
| 003 | DE-627 | ||
| 005 | 20230308115349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23876/j.krcp.19.082 |2 doi | |
| 035 | |a (DE-627)DOAJ046957529 | ||
| 035 | |a (DE-599)DOAJbc22bc83d00748908adc6171168b5316 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RC31-1245 | |
| 050 | 0 | |a RC581-951 | |
| 100 | 0 | |a Yu Ho Lee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of online hemodiafiltration on anemia and nutritional status in chronic hemodialysis patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background : : Online hemodiafiltration (OL-HDF) offers considerable advantages in clearance of molecules of various sizes. However, evidence of clinical effects of OL-HDF is scarce in Korea. In this study, we investigated changes in laboratory values over more than 12 months after switching to OL-HDF. Methods : : Adult patients with end-stage renal disease undergoing hemodialysis (HD) were prospectively enrolled in a K-cohort (CRIS no. KCT0003281) from 6 tertiary hospitals in South Korea. We recruited 435 patients, 339 of whom were on HD at enrollment. One hundred eighty-two patients were followed for more than 24 months. Among them, 44 were switched to OL-HDF for more than 12 months without conversion to HD. We used a paired t test to compare baseline and 24-month follow-up results. Results : : The mean age of the subjects was 61.2 ± 12.2 years, and 62.6% were male. The baseline hemoglobin level was not significantly different between HD and OL-HDF group (10.61 ± 1.15 vs. 10.46 ± 1.03 g/dL, P = 0.437). However, the baseline serum protein and albumin levels were significantly lower in the OL-HDF group (6.82 ± 0.49 vs. 6.59 ± 0.48 g/dL, P = 0.006; 3.93 ± 0.28 vs. 3.73 ± 0.29 g/dL, P < 0.001). In patients switched to OL-HDF, levels of hemoglobin and serum albumin significantly increased (10.46 ± 1.03 vs. 11.08 ± 0.82 g/dL, P = 0.001; 3.73 ± 0.29 vs. 3.87 ± 0.30 g/dL, P = 0.001). The normalized protein catabolic rate decreased after 24 months, but the change was not significant (1.07 ± 0.25 vs. 1.03 ± 0.21 g/kg/day, P = 0.433). Although the dose of erythropoiesis-stimulating agent was lower in patients who converted to HDF, it was not significantly different (-115.7 ± 189.7 vs. -170.5 ± 257.1 P = 0.206). Conclusion : : OL-HDF treatment over more than 12 months was associated with no harmful effects on anemia and nutritional status. | ||
| 650 | 4 | |a anemia | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a kidney failure | |
| 650 | 4 | |a chronic | |
| 650 | 4 | |a hemodiafiltration | |
| 650 | 4 | |a nutritional status | |
| 653 | 0 | |a Internal medicine | |
| 653 | 0 | |a Specialties of internal medicine | |
| 700 | 0 | |a Yoon Soo Shin |e verfasserin |4 aut | |
| 700 | 0 | |a So-Young Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Yang Gyun Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Sang Ho Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Ju Young Moon |e verfasserin |4 aut | |
| 700 | 0 | |a Kyung Hwan Jeong |e verfasserin |4 aut | |
| 700 | 0 | |a Hyeon Seok Hwang |e verfasserin |4 aut | |
| 700 | 0 | |a Shin Young Ahn |e verfasserin |4 aut | |
| 700 | 0 | |a Hong Joo Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Dong-Young Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Eun-Jung Ko |e verfasserin |4 aut | |
| 700 | 0 | |a Hye Jeong Cho |e verfasserin |4 aut | |
| 700 | 0 | |a Dong Ho Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Hye Yun Jeong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Kidney Research and Clinical Practice |d The Korean Society of Nephrology, 2018 |g 39(2020), 1, Seite 103-111 |w (DE-627)DOAJ000113328 |x 22119140 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2020 |g number:1 |g pages:103-111 |
| 856 | 4 | 0 | |u https://doi.org/10.23876/j.krcp.19.082 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/bc22bc83d00748908adc6171168b5316 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.23876/j.krcp.19.082 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2211-9132 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2020 |e 1 |h 103-111 | ||